Advanced research and proprietary knowledge at Versameb led to the discovery of mechanisms that could circumvent some of the above challenges. Versameb’s proprietary modifications of mRNA molecules translate into tailor-made protein expression and targeting by safely shuttling the therapy directly to their destination. This optimization increases the therapeutic window and allows access to different disease targets and various cell types which were not amenable by common mRNA approaches.
Currently, we have PoC in different tissues and for different protein classes including growth factors, hormones, cytokines. A significant increase in protein production as well as accelerated functional regeneration has been proven in various preclinical studies in regenerative medicine. Our platform works as an innovation engine allowing us to rapidly generate new molecules for different targets and tissues. The team is first focused in areas where localized delivery is possible to maximize the benefit of applying therapeutic proteins without the challenges of systemic administration. The company is rapidly expanding into potential new targets and indications.